EUCTR2009-015681-55-AT进行中（未招募）不适用
A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatmentof Exudative Age-Related Macular Degeneration - Wet AMD AL-39324 Treatment Examination (WALTZ)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient must be willing to give written informed consent, make the required study visits and follow instructions
- •2.Patient must be 50 years of age or older
- •3.The study eye must have:
- •primary subfoveal choroidal neovascularization (CNV) secondary to AMD, including predominantly classic, minimally classic or occult lesions
- •a lesion area < 12 disc areas (30 mm2) of any lesion type (predominantly classic, minimally classic or occult)
- •the total area of CNV (including both classic and occult components)
- •must comprise = 50% of the total lesion area; total lesion area is
- •defined as the area with angiographic evidence of neovascularization
- •associated contiguous areas of serous elevation of the RPE, elevated
- •blocked fluorescence, and/or late staining
- •a new diagnosis of exudative AMD or evidence of recent disease progression within the last 3 months; if the CNV in the study eye is minimally classic or occult, evidence of recent disease progression is defined as having experienced a loss of at least 1 line of vision (5 ETDRS letters or one Snellen line), a change in lesion size of more than 2.54 mm2 (1 disc area) or the appearance of new blood in the lesion
- •retinal edema as measured by a central retinal thickness of >340 µm using a Spectralis OCT imaging system
- •a best-corrected visual acuity (BCVA) ranging between 73 letters (20/40 Snellen equivalent) and 34 letters (20/200 Snellen equivalent), inclusive
- •clear ocular media and adequate pupil dilation to permit good quality photographic imaging
- •4.Patient’s fellow eye best corrected visual acuity (BCVA) must be 34 letters (Snellen equivalent 20/200) or better
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient has received any previously administered therapy, approved or investigational, for exudative AMD in the study eye
- •2.Any current or history of ocular disease in the study eye that, in the opinion of the Investigator, may confound assessment of the macula or affect central vision, other than non-exudative AMD (for example: vein occlusion, diabetic retinopathy, uveitis, angioid streaks, histoplasmosis, pathological myopia, retinal detachment, epiretinal membrane, macular hole)
- •3.Any active intraocular inflammation in the study eye.
- •4.Any evidence in the study eye of fibrosis or scarring within the lesion
- •5. Any vitreous hemorrhage or a history of rhegmatogenous retinal detachment in the study eye
- •6.History or evidence of the following surgeries in the study eye:
- •penetrating keratoplasty or vitrectomy
- •cataract surgery or Lasik within the last 3 months
- •OR expected to have cataract removal surgery during the study
- •7.Any active ocular infections in either eye (such as: blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis)
- •8.A history or medical diagnosis of uncontrolled glaucoma (defined as intraocular pressure >25 mmHg despite treatment with anti-glaucoma medication) or advanced glaucoma resulting in a cup/disc ratio >0.8 in the study eye or glaucoma filtration surgery in the study eye
- •9.Aphakia in the study eye or violation of the posterior capsule in the study eye, unless it occurred as a result of a YAG laser posterior capsulotomy in association with prior, posterior intraocular lens implantation
- •10.Current use or likely to require treatment with a systemic medication known to be toxic to the lens; including psoralen, risedronic acid and Tamoxifen
- •11.Current use or history of chronic therapy with systemic or topical ocular corticosteroids (defined as multiple doses taken daily for 3 or more consecutive days at any time within 6 months prior to enrollment)
- •12.History of a medical condition (disease, metabolic dysfunction, physical examination finding or clinical laboratory finding) that, in the opinion of the Investigator, would preclude scheduled study visits, completion of the study or a safe administration of study medication (e.g., unstable or progressive cardiovascular, pulmonary, Parkinson's, liver or renal disease, cancer or dementia)
- •12.Any screening laboratory result (hematology, serum chemistry or urinalysis) that in the opinion of the Investigator is not suitable for study participation; any screening liver function test value [AST (SGOT), ALT (SPGT), alkaline phosphatase, GGT, total bilirubin, direct bilirubin, indirect bilirubin, and LDH] that is more than twice the upper limit of normal
- •13.History of severe or serious hypersensitivity to any components of the test article (see Section 6.1.1. Study Medication), control article or clinically relevant sensitivity to fluorescein dye, as assessed by the Investigator
- •14.Female of childbearing potential (those who are not surgically sterilized or post-menopoausal) may not participate in the study if any of the following conditions exist:
- •Pregnant (positive serum pregnancy test at screening) or intend to become pregnant
- •Nursing (lactating)
- •Do not agree to use adequate birth control methods for the duration of the study (adequate birth control methods are: hormonal –oral, implantable, transdermal or injectable contraceptives; mechanical – spermicide in conjunction with a barrier such as condom or
研究者
相似试验
进行中（未招募）
1 期
Dose-Escalation Study of AL-39324 Suspension versus Lucentis for the Treatment of Exudative AMDExudative Age-related macular degenerationMedDRA version: 14.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2009-015681-55-DEAlcon Research, Ltd.
已完成
2 期
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment ExaminationAge Related Macular DegenerationNCT00992563Alcon Research35
进行中（未招募）
不适用
Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions - GBCKType II Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-005128-10-DKEli Lilly and Company - Indianapolis225
已完成
2 期
Effects of LY2189265 on Glycemic Control in Patients With Type 2 DiabetesCTRI/2009/091/000105Eli Lilly168
已完成
不适用
Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid tumoursAdvanced/metastatic Solid TumorMalignant solid tumor10027655NL-OMON47049Institut de Recherches Internationales Servier I.R.I.S24